-

SpineGuard announces its 2025 financial calendar

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, announced today its schedule for the publication of financial information for 2025.

2025 financial calendar

Event

Date*

2024 Full-Year Sales

January 10, 2025

2024 Full-Year Results

April 15, 2025

2025 First-Quarter Sales

April 15, 2025

Annual Shareholders Meeting

June 11, 2025 (1st summoning)
July 2, 2025 (2nd summoning if required)

2025 First-Half Sales

July 9, 2025

2025 First-Half Results

September 10, 2025

2025 Third-Quarter Sales

October 9, 2025

Note (*): Press releases are published after stock market closes. This information is subject to modification.

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 100,000 surgical procedures have been secured worldwide thanks to DSG® and 34 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG® technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tel.: 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Aurélie Manavarere
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

SpineGuard

BOURSE:ALSGD

Release Versions

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tel.: 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Aurélie Manavarere
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

More News From SpineGuard

SpineGuard Announces the Commercial Launch of its “PsiFGuard” New Smart Drilling Device Dedicated to Sacroiliac Joint Fusion

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announces that its commercial partner Omnia Medical launched their codeveloped product PsiFGuard in the USA during the NANS (North American Neuromodulation Society) convention in Orlando, Florida (USA) from January 30th to February 1...

SpineGuard Reports Its Full-Year 2024 Revenue

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today reports its full-year 2024 revenue. Pierre Jérôme, Chairman, CEO and co-founder of SpineGuard, said: "After a particularly challenging 2023 due to the termination of two important commercial agreements, SpineGuard is back to growth i...

SpineGuard Completes a Bond Financing to Support the Deployment of Its New Products

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, announces the completion of a bond financing agreement of an amount up to €1 million and the subscription of 100.000 euros to support the commercialization of its two new products featuring DSG® technology: Threaded PediGuard for anterior...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.